ACADIA Pharmaceuticals Inc.
ACADNext catalyst
Pimavanserin
Agitation and Aggression in Alzheimer's Disease
Get an email about ACAD's next catalysts
Track ACADIA Pharmaceuticals (ACAD) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 0 past
ACAD Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $0.21 | FQ end Sep/2026 | Call: amc
Pimavanserin Phase 2 Est. Readout
Estimated primary completion for Pimavanserin trial (NCT05895513) in Intermittent Explosive Disorder. Topline data typically follows completion by weeks to months.
SourceACP-211 Phase 2 Est. Readout (NORLIGHT)
Primary completion for ACP-211 trial (NCT07284667) in Major Depressive Disorder (MDD)
SourceMarket Overview
Stock performance and key metrics
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
WebsiteCarbetocin
Hyperphagia in Prader-Willi Syndrome
Trofinetide
Rett Syndrome
Pimavanserin
Agitation and Aggression in Alzheimer's Disease
ACP-204
Lewy Body Dementia Psychosis
Pimavanserin tartrate (ACP-103)
Parkinson's Disease Psychosis
pimavanserin tartrate
Parkinson's Disease Psychosis
ACP-044 Dose B
Acute Postoperative Pain
ACP-103
Hallucinations
ACP-104
Schizophrenia
ACP-211
Major Depressive Disorder (MDD)
Active drug: pimavanserin (2 strength tablets)
Parkinson Disease
ACP-044 Dose A
Acute Postoperative Pain
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Carbetocin | Phase 3 | Hyperphagia in Prader-Willi Syndrome | - | - |
Trofinetide | Phase 3 | Rett Syndrome | - | - |
Pimavanserin | Phase 3 | Agitation and Aggression in Alzheimer's Disease | - | - |
ACP-204 | Phase 3 | Lewy Body Dementia Psychosis | - | - |
Pimavanserin tartrate (ACP-103) | Phase 3 | Parkinson's Disease Psychosis | - | - |
pimavanserin tartrate | Phase 3 | Parkinson's Disease Psychosis | - | - |
ACP-044 Dose B | Phase 2 | Acute Postoperative Pain | - | - |
ACP-103 | Phase 2 | Hallucinations | - | - |
ACP-104 | Phase 2 | Schizophrenia | - | - |
ACP-211 | Phase 2 | Major Depressive Disorder (MDD) | - | - |
Active drug: pimavanserin (2 strength tablets) | Phase 2 | Parkinson Disease | - | - |
ACP-044 Dose A | Phase 2 | Acute Postoperative Pain | - | - |
Parkinson's Disease Psychosis
2 drugs in this indication
Acute Postoperative Pain
1 drug in this indication
Agitation and Aggression in Alzheimer's Disease
1 drug in this indication
Rett Syndrome
1 drug in this indication
Hallucinations
1 drug in this indication
Schizophrenia
1 drug in this indication
Lewy Body Dementia Psychosis
1 drug in this indication
Hyperphagia in Prader-Willi Syndrome
1 drug in this indication
Adjunctive Treatment of Major Depressive Disorder
1 drug in this indication
Dementia-related Psychosis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in ACADIA Pharmaceuticals Inc.'s drug pipeline?→
CatalystAlert tracks 12 drug candidates in ACADIA Pharmaceuticals Inc.'s (ACAD) pipeline across Phase 3, Phase 2. Its lead program is Pimavanserin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ACADIA Pharmaceuticals Inc.'s next FDA catalyst?→
ACADIA Pharmaceuticals Inc.'s (ACAD) next tracked catalyst is a Phase 2 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ACAD biotech catalysts?→
Add ACAD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ACADIA Pharmaceuticals Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.